TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17295632

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 15522553

Group type: EXPERIMENTAL
Intervention: 5‐fluoro‐uracyl‐epirubicin‐cyclophosphamide (FEC) - six cycles
Number of subjects: 40

Group type: COMPARATOR
Intervention: docetaxel‐based chemotherapy - six cycles (DXL-epirubicin: 13 patients, DXL alone: 15 patients)
Number of subjects: 40
Study: 11553189

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.i.d. for 6 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study: 8831216

Group type: EXPERIMENTAL
Intervention: 100 ml Iopamidol (300 mgI/ml), at a rate of 2 ml/sec
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 120 ml, 3 ml/sec
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 150 ml, 3 ml/sec
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: biphasic method, initial 100 ml, 3.3 ml/sec; remaining 50 ml, 1.6 ml/sec
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: three-phase dynamic helical CT using protocol (4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: three-phase dynamic helical CT
Number of subjects: 20
Study: 2248385

Group type: EXPERIMENTAL
Intervention: Epidural morphine and clonidine (group 1; n = 45)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Epidural morphine alone (group 2; n = 46)
Number of subjects: 91
Study: 7437248

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg daily for 8 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (daily for 8 days)
Number of subjects: 8
Study: 30461542

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tocilizumab and Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept and Ustekinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab and Tumor Necrosis Factor Inhibitors (including Certolizumab)
Number of subjects: 0
Study: 26708726

Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) plus standardized nutritional counseling
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standardized nutritional counseling only (Control)
Number of subjects: 107
Study: 25982143

Group type: EXPERIMENTAL
Intervention: Low saturated fat-oriented dietary intervention
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Adiponectin ≤ median
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 521
Study: 25467396

Group type: EXPERIMENTAL
Intervention: Mental practice (MP) and mirror therapy (MT) associated with conventional physical therapy training (CPTT)
Number of subjects: 7
Study: 22788263

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) added to stimulant monotherapy
Number of subjects: 461

Group type: COMPARATOR
Intervention: Stimulant monotherapy
Number of subjects: 461
Study: 21068701

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 253
Study: 17880485

Group type: EXPERIMENTAL
Intervention: Peer education programme consisting of four one-hour sessions targeting evidence-based knowledge, myths and misconceptions, normative, attitudinal and control influences over evidence-based fever management.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 15479705

Group type: EXPERIMENTAL
Intervention: PACE intervention (two visits with GP and two telephone booster calls by a physical activity counselor)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: PACE intervention
Number of subjects: 29
Study: 12296775

Group type: EXPERIMENTAL
Intervention: Ultra Sonex Ultima (electric toothbrush)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 64
Study: 10063307

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) with prednisolone withdrawal
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional hepatotonics
Number of subjects: 32
Study: 8803516

Group type: EXPERIMENTAL
Intervention: 2.5 mg imidapril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg imidapril
Number of subjects: 24
Study: 1611460

Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation (1.25 g day‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 6322734

Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31371195

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (1.5 mg kg‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham blocks with saline
Number of subjects: 20
Study: 30305186

Group type: EXPERIMENTAL
Intervention: Partograph utilization
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Diploma holders
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Basic emergency obstetrics and newborn care training
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Age between 20 and 29 years
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Male health care providers
Number of subjects: 198
Study: 27765750

Group type: EXPERIMENTAL
Intervention: High-dose ebselen (150 mg po twice daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 24607602

Group type: EXPERIMENTAL
Intervention: Physiotherapist-led cycle ergometer exercise (30 min, moderate intensity) plus one equivalent unsupervised exercise session, 8-week duration.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 59
Study: 22889179

Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice + CO2 laser
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride anticavity dentifrice
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride anticavity dentifrice + CO2 laser
Number of subjects: 10
Study: 19902197

Group type: EXPERIMENTAL
Intervention: Racecadotril 100 mg every 8 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide 2.0 mg followed by one tablet after each unformed stool, up to four tablets in any 24-h period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study: 17923225

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (Clearfil SE Bond, CSE) with no conditioning
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 30-40% phosphoric acid (PA) preconditioning after bleaching
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 15% EDTA preconditioning after TM application
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 20% polyacrylic acid conditioner (Cavity conditioner, CC) preconditioning after TM application
Number of subjects: 35

Group type: COMPARATOR
Intervention: Total‐etch adhesive (Single Bond, SB)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) without preconditioning after TM application
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) after bleaching with and without TM application
Number of subjects: 35
Study: 16198201

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine
Number of subjects: 14
Study: 11834103

Group type: EXPERIMENTAL
Intervention: DAER training (3 sets of 10 repetitions with a concentric load of 75% 1RM and an eccentric load of approximately 120% 1RM)
Number of subjects: 18

Group type: COMPARATOR
Intervention: DCER training (4 sets of 10 repetitions with a load of 75% concentric 1RM)
Number of subjects: 18
Study: 9620116

Group type: EXPERIMENTAL
Intervention: PHT sodium solution 435 mg intravenously
Number of subjects: 10

Group type: COMPARATOR
Intervention: PHT acid suspension 400 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PHT sodium solution 435 mg
Number of subjects: 10
Study: 7613158

Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 0
Study: 2191992

Group type: EXPERIMENTAL
Intervention: Single dose of methylprednisolone (40 mg bolus)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Divided regimen of methylprednisolone (20 mg bolus and 5 mg bolus 8 hours later)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both regimens of methylprednisolone
Number of subjects: 6
Study: 475363

Group type: EXPERIMENTAL
Intervention: Aminoglycoside treatment (gentamicin, tobramycin, or amikacin)
Number of subjects: 391
Study: 31679069

Group type: EXPERIMENTAL
Intervention: Early functional mobilization (encouraging full weightbearing and ankle motion in orthosis)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Treatment-as-usual (2 weeks of unloading in plaster cast followed by 4 weeks weightbearing in orthosis)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Early functional mobilization
Number of subjects: 150
Study: 31097854

Group type: EXPERIMENTAL
Intervention: BB + Amiodarone
Number of subjects: 240

Group type: COMPARATOR
Intervention: BB (comparator)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BB + Rosuvastatin
Number of subjects: 240
Study: 28072888

Group type: EXPERIMENTAL
Intervention: Simeprevir plus peg‐interferon/ribavirin (PR) for 12 weeks followed by 12 or 36 weeks of PR
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Early on-treatment response at Week 4
Number of subjects: 1160
Study: 25726515

Group type: EXPERIMENTAL
Intervention: Acute kidney injury alert (text-based alert sent to the covering provider and unit pharmacist)
Number of subjects: 2393

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2393

Group type: EXPERIMENTAL
Intervention: Acute kidney injury alert
Number of subjects: 2393
Study: 23771840

Group type: EXPERIMENTAL
Intervention: DSME/T plus MARI CD
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: DSME/T plus MT
Number of subjects: 199

Group type: COMPARATOR
Intervention: DSME/T alone
Number of subjects: 199
Study: 21561391

Group type: COMPARATOR
Intervention: Chapattis containing 0% β-glucan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chapattis containing 4% β-glucan
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chapattis containing 8% β-glucan
Number of subjects: 10
Study: 19425198

Group type: EXPERIMENTAL
Intervention: Hexadecyloxypropyl‐cidofovir (CMX001)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexadecyloxypropyl‐tenofovir (CMX157)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alkoxyalkyl esters of cidofovir and (S)‐HPMPA
Number of subjects: 0
Study: 17623958

Group type: EXPERIMENTAL
Intervention: Intravenous PCA tramadol (loading dose of 2.5 mg/kg followed by PCA infusion of 10 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous PCA morphine (loading dose of 0.1 mg/kg followed by PCA morphine bolus of 1 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Intravenous PCA tramadol
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous PCA morphine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 14586478

Group type: EXPERIMENTAL
Intervention: Supportive care strategies
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Infection-associated complications
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Infectious complications
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Blood stream infections
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Invasive fungal infection
Number of subjects: 304
Study: 11157376

Group type: EXPERIMENTAL
Intervention: 2 mg of warfarin daily for 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Disease control group (30 healthy volunteers)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Treatment group (n = 29)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Disease control group (n = 31)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 76
Study: 9395349

Group type: EXPERIMENTAL
Intervention: Zanamivir (GG167) intranasally as prophylaxis
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Zanamivir (GG167) intranasally as early treatment
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study: 8203783

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (micronized flavonoidic fraction)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonmicronized diosmin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 90
Study: 3302568

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Dusodril) in combination with cortison and dextran
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Pentoxifyllin (Trental) in combination with cortison and dextran
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Long-term treatment with either naftidrofuryl or pentoxifyllin
Number of subjects: 151
Study: 29495483

Group type: EXPERIMENTAL
Intervention: Household water treatment systems (biosand zeolite-silver impregnated granular clay filters and silver-impregnated porous pot filters) installed in 372 participants from 70 households.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group (108 participants from 18 households who did not accept the installation of the systems).
Number of subjects: 480
Study: 24622667

Group type: EXPERIMENTAL
Intervention: Stepwise addition of bolus insulin (one bolus dose with the largest meal, additional doses at 11 and 22 weeks if HbA1c remained at 7% or higher)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Full basal-bolus therapy (insulin aspart before every meal)
Number of subjects: 401
Study: 22537390

Group type: EXPERIMENTAL
Intervention: Mother/infant skin-to-skin contact (SSC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (little or no SSC)
Number of subjects: 90
Study: 19437243

Group type: EXPERIMENTAL
Intervention: Guided active play/physical activity, 60 minutes, twice a week for 5 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (dietary advice and encouragement to increase physical activity only)
Number of subjects: 60
Study: 18325693

Group type: EXPERIMENTAL
Intervention: Alcohol dose of 0.65 g/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 15769980

Group type: EXPERIMENTAL
Intervention: 3 mg dexamethasone twice daily for 5 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 12479641

Group type: EXPERIMENTAL
Intervention: DFDBA/MGCSH
Number of subjects: 13

Group type: COMPARATOR
Intervention: DFDBA/ePTFE
Number of subjects: 13
Study: 10401515

Group type: EXPERIMENTAL
Intervention: Naloxone (0, 0.8, 1.6, or 3.2 mg/70 kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (lower doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone challenge
Number of subjects: 20
Study: 7745488

Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 30

Group type: COMPARATOR
Intervention: No facilitated tucking
Number of subjects: 30
Study: 1693037

Group type: EXPERIMENTAL
Intervention: Allylestrenol (ALE) 50 mg/day for 12 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) 50 mg/day for 12 weeks
Number of subjects: 58
Study: 331522

Group type: EXPERIMENTAL
Intervention: Fluorouracil intraluminal chemotherapy
Number of subjects: 500
Study: 30949704

Group type: EXPERIMENTAL
Intervention: Intravenous lefamulin (150 mg, q12h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lefamulin (600 mg IR tablet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lefamulin (3 × 200 mg capsule)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral lefamulin (IR) in fasted state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated doses of lefamulin (IR, q12h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27804233

Group type: EXPERIMENTAL
Intervention: Irbesartan treatment
Number of subjects: 82
Study: 26209860

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg/d)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Amisulpride (200 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23566360

Group type: EXPERIMENTAL
Intervention: Telephone-based intervention with four telephone contacts and print materials
Number of subjects: 394

Group type: COMPARATOR
Intervention: Control condition with generic print materials only
Number of subjects: 394
Study: 21611863

Group type: EXPERIMENTAL
Intervention: Group Slow (1 ml/min injection of hyperbaric 0.5% bupivacaine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Group Extra Slow (0.5 ml/min injection of hyperbaric 0.5% bupivacaine)
Number of subjects: 66
Study: 19912734

Group type: EXPERIMENTAL
Intervention: Sanxue Mingmu Tablet combined with conventional treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Xueshuantong Tablet combined with conventional treatment
Number of subjects: 34
Study: 16698412

Group type: EXPERIMENTAL
Intervention: Intranasal lorazepam (100 microg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intramuscular paraldehyde (0.2 mL/kg)
Number of subjects: 160
Study: 15138466

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard therapy as perceived by medical oncologists
Number of subjects: 0
Study: 11336276

Group type: EXPERIMENTAL
Intervention: Thin-layer chromatography (TLC) screening method for drug quality
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Confirmatory analysis for RMP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Confirmatory analysis for INH
Number of subjects: 40
Study: 9466167

Group type: EXPERIMENTAL
Intervention: RS-8359 100 mg/day
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RS-8359 200 mg/day
Number of subjects: 2

Group type: COMPARATOR
Intervention: Moclobemide 300 mg/day
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RS-8359 (all doses)
Number of subjects: 2
Study: 7949088

Group type: EXPERIMENTAL
Intervention: rHuEPO (150 IU/kg/day)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: rHuEPO
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 2833980

Group type: EXPERIMENTAL
Intervention: 21G needle passed into the tumour at least 10 times
Number of subjects: 19

Group type: COMPARATOR
Intervention: 23G needle
Number of subjects: 19

Group type: COMPARATOR
Intervention: 21G needle
Number of subjects: 19

Group type: COMPARATOR
Intervention: 19G needle
Number of subjects: 19

Group type: COMPARATOR
Intervention: 5 passes
Number of subjects: 19

Group type: COMPARATOR
Intervention: 10 passes
Number of subjects: 19

Group type: COMPARATOR
Intervention: 15 passes
Number of subjects: 19
Study: 29531468

Group type: EXPERIMENTAL
Intervention: PGA plus stent placement
Number of subjects: 70

Group type: COMPARATOR
Intervention: Stent placement alone
Number of subjects: 70
Study: 28534875

Group type: EXPERIMENTAL
Intervention: 8 IU oxytocin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 24 IU oxytocin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26231052

Group type: EXPERIMENTAL
Intervention: Incontinence Utility Index (IUI)
Number of subjects: 1105
Study: 23926589

Group type: EXPERIMENTAL
Intervention: 11 different toothbrushes (Colgate Massager, Butler 311, Gum Super Tip 463, Oral-B Indicator 35, Colgate Omni, Gum Technique 493)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Colgate Massager
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral-B Indicator 35
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no toothbrushing)
Number of subjects: 48
Study: 21148715

Group type: EXPERIMENTAL
Intervention: Breathe-Easy home (BEH)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Previous asthma-control intervention (control group)
Number of subjects: 102
Study: 18978620

Group type: EXPERIMENTAL
Intervention: Squat training with whole-body low-frequency vibration (SQTV)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Squat training without vibration (SQT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30-cm depth jump Pmax percent change
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20-kg squat jump Pmax
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20-kg squat jump Pmax/kg percent change
Number of subjects: 30
Study: 17120390

Group type: EXPERIMENTAL
Intervention: xenograft plus fibronectin
Number of subjects: 24

Group type: COMPARATOR
Intervention: xenograft without fibronectin
Number of subjects: 24
Study: 15650065

Group type: EXPERIMENTAL
Intervention: Plasma arc lamp
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional tungsten quartz halogen lamp
Number of subjects: 20
Study: 11317156

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program (n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-exercise control group (n = 13)
Number of subjects: 26
Study: 9146907

Group type: EXPERIMENTAL
Intervention: Stimulus duration of 200 to 1500 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 7711427

Group type: EXPERIMENTAL
Intervention: captopril
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 2895695

Group type: EXPERIMENTAL
Intervention: Exercise (game of squash)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rest after exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Beta 2-antagonist pretreatment
Number of subjects: 6
Study: 31221941

Group type: EXPERIMENTAL
Intervention: Leukocytapheresis (LCAP) therapy (n = 20)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Disease-modifying antirheumatic drugs (DMARDs) (n = 31)
Number of subjects: 51
Study: 30621787

Group type: EXPERIMENTAL
Intervention: Back2School (modular transdiagnostic cognitive behavioral therapy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Back2School
Number of subjects: 160
Study: 28687477

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827